Role of adrenomedullin in glioblastomas growth;Invasion et angiogenèse dans les gliomes: Rôle de l'adrénomédulline

Bulletin du Cancer

Volumn 92, Issue 4, 2005, Pages 317-326

  Boudouresque, Françoise ^a   Berthois, Yolande ^a   Martin, Pierre Marie ^a,c   Figarella Branger, Dominique ^d   Chinot, Olivier ^a,b   Ouafik, L'Houcine ^a  

^a INSERM   (France)

^b TIMONE HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Adrenomedullin; Glioma

Indexed keywords

ADRENOMEDULLIN; ADRENOMEDULLIN RECEPTOR; CALCITONIN RECEPTOR LIKE RECEPTOR; GROWTH FACTOR; MESSENGER RNA; PROTEIN ANTIBODY; RECEPTOR ACTIVITY MODIFYING PROTEIN; RECEPTOR ACTIVITY MODIFYING PROTEIN 2; RECEPTOR ACTIVITY MODIFYING PROTEIN 3; UNCLASSIFIED DRUG; ANGIOGENIC PROTEIN; NEUROPEPTIDE; PEPTIDE; TUMOR PROTEIN;

ANGIOGENESIS; ARTICLE; AUTOCRINE EFFECT; CORRELATION ANALYSIS; ENDOTHELIUM CELL; FATALITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOGENESIS; NEOVASCULARIZATION (PATHOLOGY); PARACRINE SIGNALING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; TUMOR GROWTH; XENOGRAFT; ASTROCYTOMA; BRAIN TUMOR; CANCER INVASION; CELL HYPOXIA; METABOLISM; OLIGODENDROGLIOMA; PATHOLOGY; PHYSIOLOGY; REVIEW;

ADRENOMEDULLIN; ANGIOGENIC PROTEINS; ASTROCYTOMA; BRAIN NEOPLASMS; CELL HYPOXIA; GLIOBLASTOMA; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NEUROPEPTIDES; OLIGODENDROGLIOMA; PEPTIDES;

EID: 18344387968     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Holland EC. Gliomagenesis: genetic alterations and mouse models. Nature Rev Genet 2001; 2: 120-9.
2. Folkman J. Aogiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
3. Gerwins P, Skoldenberg E, Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelial growrh factors and their receptors in angiogenesis. Crit Rev Oncol Hematol 2000; 34: 185-94.
4. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003; 4: 33-45.
5. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1990; 80: 353-04.
6. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845-8.
7. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-8.
8. Arap W, Pasqualini R, Ruoslahti E. Chemotherapy targeted to tumor vasculature. Curr Opin Oncol 1998; 10: 560-5.
9. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5: 1359-64.
10. Borgstrom P, Hillan KJ, Sriramarao P, Fertara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996; 56: 4032-9.
11. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-9.
12. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, et al. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996; 56: 3540-5.
13. Moody TW, Pert CB, Gazdar AF, Carney DN, Minna JD. High levels of intracellular bombesin characterize human small-cell lung carcinoma. Science 1981; 214: 1246-8.
14. Desmond H, Pauwels S, Varro A, Gregory H, Young J, Dockray GJ. Isolation and characterization of the intact gastrin precursor from a gastrinoma. FEBS Lett 1981; 210: 185-8.
15. Moody TW, Mahmoud S, Staley J, Naldini L, Cirillo D, South V, et al. Human 15 glioblastoma cell lines have neuropeptide receptors for bombesin/gastrin-releasing peptide. J Mol Neurosci 1989; 1: 235-42.
16. Martin DL. Synthesis and release of neuroactive substances by glial cells. Glia 1992; 5: 81-94.
17. Dalsgaard CJ, Hultgardh-Nilsson A, Haegerstrand A, Nilsson J. Neuro-peptides as growth factors. Possible roles in human diseases. Regul Pept 1989; 25: 1-9.
18. Brenneman DE, Nicol T, Warren D, Bowers LM. Vasoactive intestinal peptide: a neurotrophic releasing agent and an astroglial mitogen. J Neurosci Res 1990; 25: 386-94.
19. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 1998; 83: 187-95.
20. Miller MJ, Martinez A, Unsworth EJ, Thiele CJ, Moody TW, Elsasser T, et al. Adrenomedullin expression in human tumor cell lines. Its potential role as an autocrine growth factor. J Biol Chem 1996; 271: 23345-51.
21. Rocchi P, Boudouresque F, Zamora AJ, Muracciole X, Lechevallier E, Martin PM, et al. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines. Cancer Res 2001; 61: 1196-206.
22. Takahashi K, Satoh F, Hara E, Murakami O, Kumabe T, Tominaga T, et al. Production and secretion of adrenomedullin by cultured chotoid plexus carcinoma cells. J Neurochem 1997; 68: 726-31.
23. Takahashi K, Satoh F, Hara E, Sone M, Murakami O, Kayama T, et al. Production and secretion of adrenomedullin from glial cell tumors and its effects on cAMP production. Peptides 1997; 18: 1117-24.
24. Murakami O, Takahashi K, Satoh F, Totsune K, Sone M, Arihara Z, et al. Expression of adrenomedullin and adrenomedullin mRNA in ectopic ACTH-secreting tumors. Eur J Endocrinol 1998; 138: 436-9.
25. Withers DJ, Coppock HA, Seufferlein T, Smith DM, Bloom SR, Rozengurt E. Adrenomedullin stimulates DNA synthesis and cell proliferation via elevation of cAMP in Swiss 3T3 cells. FEBS Lett 1996; 378: 83-7.
26. Zhao Y, Hague S, Manek S, Zhang L, Bicknell R, Rees MC. PCR display identifies ramoxifen induction of the novel angiogenic factor adrenomedullin by a non estrogenic mechanism in the human endometrium. Oncogene 1998; 16: 409-15.
27. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993; 192: 553-60.
28. Ishizaka Y, Tanaka M, Kitamura K, Kangawa K, Minamino N, Matsuo H, et al. Adrenomedullin stimulates cyclic AMP formation in rat vascular smoorh muscle cells. Biochem Biophys Res Commun 1994; 200: 642-6.
29. Ishimitsu T, Kojima M, Kangawa K, Hino J, Matsuoka H, Kiramura K, et al. Genomic structure of human adrenomedullin gene. Biochem Biophys Res Commun 1994; 203: 631-9.
30. Ouafik L'H, Giraud P, Salers P, Oliver C. La peptidylglycine α-amidating monooxygenase (PAM), une enzyme bifonctionnelle catalysant l'α-amidation de peptides. Med Sci (Paris) 1991; 7: 927-35.
31. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor- like receptor. Nature 1998; 393: 333-9.
32. Buhlmann N, Leuthauser K, Muff R, Fischer JA, Born W. A receptor activity modifying protein (RAMP) 2-dependent adrenomedullin receptor is a calcitonin gene-telated peptide receptor when coexpressed with human RAMP1. Endocrinology 1999; 140: 2883-90.
33. Evans BN, Rosenblatt MI, Mnayer LO, Oliver KR, Dickerson IM. CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J Biol Chem 2000; 275: 31438-43.
34. Kuwasako K, Kitamura K, Ito K, Uemura T, Yanagita Y, Kato J, et al. The seven amino acids of human RAMP2 (86) and RAMP3 (59) are critical for agonist binding to human adtenomedullin receptors. J Biol Chem 2001; 276: 49459-65.
35. Sexton PM, Albiston A, Morfis M, Tilakatatne N. Receptor activity modifying proteins. Cell Signal 2001; 13: 73-83.
36. Ichiki Y, Kitamura K, Kangawa K, Kawamoto M, Matsuo H, Eto T. Distribution and chatacterization of immunoteacrive adrenomedullin in human tissue and plasma. FEBS Lett 1994; 338: 6-10.
37. Washimine H, Asada Y, Kitamuta K, Ichiki Y, Hara S, Yamamoto Y, et al. Immunohistochemical identification of adrenomedullin in human, rat, and potcine tissue. Histochem Cell Biol 1995; 103: 251-4.
38. Asada Y, Hara S, Matutsuka K, Kitamura K, Tsuji T, Sakata J, et al. Novel distribution of adrenomedullin-immunoreactive cells in human tissues. Histochem Cell Biol 1999; 112: 185-91.
39. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000; 21: 138-67.
40. Cheung B, Leung R. Elevated plasma levels of human adrenomedullin in cardiovascular, respiratory, hepatic and renal disorders. Clin Sci (Lond) 1997; 92: 59-62.
41. Richards AM, Nicholls MG, Lewis L, Lainchbuty JG. Adrenomedullin. Clin Sci (Lond) 1996; 91: 3-16.
42. Samson WK. Adrenomedullin and the control of fluid and electrolyte homeostasis. Annu Rev Physiol 1999; 61: 363-89.
43. Sugo S, Minamino N, Shoji H, Kangawa K, Kitamura K, Eto T, et al. Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor-alpha. Biochem Biophys Res Commun 1994; 203: 719-26.
44. Sugo S, Minamino N, Shoji H, Kangawa K, Kitamura K, Eto T, et al. Interleukin-1, tumor necrosis factor and lipopolysaccharide additively stimulate production of adrenomedullin in vascular smooth muscle cells. Biochem Biophys Res Commun 1995; 207: 25-32.
45. Yoshihara F, Horio T, Nishikimi T, Matsuo H, Kangawa K. Possible involvement of oxidative stress in hypoxia-induced adrenomedullin secretion in cultured rat cardiomyocytes. Eur J Pharmacol 2002; 436: 1-6.
46. Cormier-Regard S, Nguyen SV, Claycomb WC. Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes. J Biol Chem 1998; 273: 17787-92.
47. Nguyen SV, Claycomb WC. Hypoxia regulates the expression of the adrenomedullin and HIF-1 genes in cultured HL-1 cardiomyocytes. Biochem Biophys Res Commun 1999; 265: 382-6.
48. Lainchbury JG, Cooper GJ, Coy DH, Jiang NY, Lewis LK, Yandle TG, et al. Adrenomedullin: a hypotensive hormone in man. Clin Sci (Lond) 1997; 92: 467-72.
49. Meeran K, O'Shea D, Upron PD, Small CJ, Ghatei MA, Byfield PH, et al. Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J Clin Endocrinol Metab 1997; 82: 95-100.
50. Nagaya N, Satoh T, Nishikimi T, Uematsu M, Furuichi S, Sakamaki F, et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 2000; 101: 498-503.
51. Iwasaki H, Eguchi S, Shichiri M, Marumo F, Hirata Y. Adrenomedullin as a novel growth-promoting factor for cultured vascular smooth muscle cells: role of tyrosine kinase-mediated mitogen-activated protein kinase activation. Endocrinology 1998; 139: 3432-41.
52. Kano H, Kohno M, Yasunari K, Yokokawa K, Horio T, Ikeda M, et al. Adrenomedullin as a novel antiproliferative factor of vascular smooth muscle cells. J Hypertens 1996; 14: 209-13.
53. Kitamura K, Eto T. Adrenomedullin and PAMP. Nippon Rinsho 1997; 55: 1963-70.
54. Ehlenz K, Koch B, Preuss P, Simon B, Koop I, Lang RE. High levels of circulating adrenomedullin in severe illness: correlation with C-reactive protein and evidence against the adrenal medulla as site of origin. Exp Clin Endocrinol Diabetes 1997; 105: 156-62.
55. Sato K, Hitata Y, Imai T, Iwashina M, Marumo F. Charactetization of immunoreactive adrenomedullin in human plasma and urine. Life Sci 1995; 57: 189-94.
56. Ouafik L, Sauze S, Boudouresque F, Chinor O, Delfino C, Fina F, et al. Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo. Am J Pathol 2002; 160: 1279-92.
57. Lal A, Lash AE, Altschul SF, Velculescu V, Zhang L, McLendon RE, et al. A public database for gene expression in human cancers. Cancer Res 1999; 59: 5403-7.
58. Sone M, Takahashi K, Satoh F, Mutakami O, Totsune K, Ohneda M, et al. Specific adrenomedullin binding sites in the human brain. Peptides 1997; 18: 1125-9.
59. Cuttitta F, Pio R, Garayoa M, Zudaire E, Julian M, Elsasser TH, et al. Adrenomedullin functions as an important tumor survival factor in human carcinogenesis. Microsc Res Tech 2002; 57: 110-9.
60. Quinn KA, Treston AM, Unsworth EJ, Miller MJ, Vos M, Gtimley C, et al. Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 1996; 271: 11477-83.
61. Libetmann TA, Friesel R, Jaye M, Lyall RM, Westermark B, Drohan W, et al. An angiogenic growth factor is expressed in human glioma cells. EMBO J 1987; 6: 1027-32.
62. Jensen RL. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol 1998; 49: 189-95 [discussion: 196].
63. Moody TW, Miller MJ, Martinez A, Unsworth E, Cuttitta F. Adrenomedullin binds with high affinity, elevates cyclic AMP, and stimulates c-fos mRNA in C6 glioma cells. Peptides 1997; 18: 1111-5.
64. Garayoa M, Martinez A, Lee S, Pio R, An WG, Neckers L, et al. Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deptivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol 2000; 14: 848-62.
65. Kitamuro T, Takahashi K, Nakayama M, Murakami O, Hida W, Shirato K, et al. Induction of adrenomedullin during hypoxia in cultured human glioblastoma cells. J Neurochem 2000; 75: 1826-33.
66. Ogita T, Hashimoto E, Yamasaki M, Nakaoka T, Matsuoka R, Kira Y, et al. Hypoxic induction of adrenomedullin in cultured human umbilical vein endothelial cells. J Hypertens 2001; 19: 603-8.
67. Carmelier P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
68. Fernandez-Sauze S, Delfino C, Mabrouk K, Dussert C, Chinot O, Martin PM, et al. Effects of adrenomedullin on endothelial cells in the multistep process of angiogenesis: involvement of CRLR/RAMP2 and CRLR/RAMP3 receptors. Int J Cancer 2004; 108: 797-804.
69. Ishikawa T, Chen J, Wang J, Okada F, Sugiyama T, Kobayashi T, et al. Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis. Oncogene 2003; 22: 1238-42.
70. Shindo T, Kurihara Y, Nishimatsu H, Moriyama N, Kakoki M, Wang Y, et al. Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. Circulation 2001; 104: 1964-71.